Syncom Formulations (India) Limited
Quick Take
- • Trading at 22.3× trailing earnings
- • Strong ROE at 20.4%
- • Low leverage (D/E 0.00)
- • Modest dividend yield of 0.53%
- • Operating margin 19.7% · Net margin 17.2%
- • Profit growth +23.80% YoY · Beta 0.80
Latest quarter · Jun 2026
| ₹ Cr | Jun 2026 | QoQ | YoY |
|---|---|---|---|
| Revenue | 126 | -6.67% | +7.69% |
| Operating Profit | 34 | -8.11% | +54.55% |
| Net Profit | 25 | +0.00% | +56.25% |
| EPS (₹) | 0.26 | -3.70% | +52.94% |
About the company
From latest AR & concallSyncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, dry syrups and suspensions, creams, gel, ORS, jelly, gynae, inhalers, opthal, ortho, and pediatrics formulations in dosage forms. It also provides life care, evolve, and the right nutrition products under the Cratus brand. In addition, the company offers pharmaceutical formulation products in various dosage forms, such as tablets, capsules, ointments, injections, creams, liquids orals, and effervescent. Further, it provides liquid vials and ampoule injections, dry vial injections and inhalers; manufacturing and trading of nutraceuticals, dietary supplements, health supplements, functional foods, herbal and ayurvedic preparations, vitamins, minerals, proteins, antioxidants, natural extracts, organic and wellness products, and all related healthcare and nutrition-based goods and real estate business. Syncom Formulations (India) Limited was incorporated in 1988 and is based in Indore, India.
